From the nervous system: drowsiness, tremor, fatigue, insomnia, dizziness, fatigue, convulsions, extrapyramidal disorder, hallucinations, delusions, confusion, agitation, anxiety, depersonalisation, panic attacks, nervousness, paresthesia, decreased ability to concentrate, tri tren side effects serotonin syndrome
From the musculoskeletal system: arthralgia, myalgia, myopathy, myasthenia gravis
From the senses : blurred vision, change in taste
With the genitourinary system : sexual dysfunction, including impotence and ejaculation disorders, loss of libido, anorgasmia, urinary retention, increased frequency of urination.
From the digestive system: loss of appetite, nausea, vomiting, dry mouth, and constipation or diarrhea, in very rare cases – hepatitis.
Since the cardiovascular system : orthostatic hypotension.
Other: increased sweating, allergic reactions (rash, urticaria, ekhimatozy, pruritus, angioedema), hyponatremia, inappropriate secretion of antidiuretic hormone, hyperprolactinaemia / galactorrhoea, withdrawal syndrome when the drug abrupt cancellation.
Interaction with other drugs
Food intake of antacids and does not affect the absorption of the drug and pharmacokinetic parameters.
Paroxetine is incompatible with MAO inhibitors, thioridazine.
When concomitant administration of paroxetine increases concentration protsiklidina.
During treatment with paroxetine tri tren side effects should refrain from drinking alcohol in connection with a possible strengthening of the toxic effect of alcohol.
The metabolism and pharmacokinetics of paroxetine may change when coadministered with drugs inducers / inhibitors of liver enzymes.
Due to inhibition of cytochrome P450 paroxetine may increase the effect of barbiturates, phenytoin, indirect anticoagulants, tricyclic antidepressants (nortriptyline, amitriptyline, imipramine, desipramine and fluoxetine), phenothiazine neuroleptics (thioridazine) and Class 1C antiarrhythmics (including propafenone), and metoprolol increasing the risk of side effects with concomitant administration of these drugs.
When concomitant administration with drugs that inhibit the liver enzymes may require dose reduction of paroxetine.
Paroxetine increases bleeding time in patients receiving warfarin, the prothrombin time at constant.
When concomitant administration of paroxetine with atypical antipsychotics, phenothiazines, tricyclic antidepressants, aspirin, non-steroidal anti-inflammatory drugs is recommended to exercise caution due to possible bleeding disorders.
Co-administration with serotonergic drugs (tramadol, sumatriptan) may lead to increased serotonergic effect.
As with the appointment of other selective serotonin reuptake inhibitors noted mutual enhancement of the action of tryptophan, drugs lithium and paroxetine. Joint reception c lithium preparations carried out under the control of their blood concentrations.
We do not recommend co-administration with drugs containing tryptophan.
When using paroxetine with neuroleptics, as well as other selective serotonin reuptake inhibitors, may develop neuroleptic malignant syndrome.
When concomitant administration of paroxetine with phenytoin and other anticonvulsants may reduce plasma concentrations of paroxetine and an increase in the frequency of side effects.
Symptoms include nausea, vomiting, tremor, dry mouth, dilated pupils, fever, blood pressure changes, headache, involuntary muscle contractions, agitation, anxiety, sinus tachycardia, sweating, drowsiness, nystagmus, bradycardia, nodal rhythm
In very rare cases, while taking other tri tren side effects psychotropic drugs and / or alcohol may be changes in the electrocardiogram, coma.
Treatment: gastric lavage, activated charcoal. If necessary – symptomatic therapy. No specific antidote.
To prevent the development of neuroleptic malignant syndrome with caution appoint patients taking antipsychotics.
Paroxetine does not impair cognitive and psychomotor functions, however, as in the treatment of other psychotropic drugs patients should be careful when driving and moving machinery.
During the period of treatment should refrain from drinking alcohol and from activities potentially hazardous activities that require high concentration and psychomotor speed reactions.
Treatment with paroxetine administered 2 weeks after discontinuation of MAO inhibitors.
Elderly patients can hyponatremia.
In some cases, the required dose adjustment of insulin and / or oral hypoglycemic agents.
With the development of seizures, treatment with paroxetine stop.
At the first sign of mania paroxetine therapy should be discontinued.
During the first few weeks should be carefully monitored for the patient’s condition in relation to possible suicide attempts, because at this time can not yet be achieved tri tren side effects therapeutic effect of paroxetine.